These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2408194)

  • 1. [Clinical trials of the new Norwegian vaccine against diseases caused by Meningococcus B].
    Bjune G; Nøkleby H; Hareide B
    Tidsskr Nor Laegeforen; 1990 Feb; 110(5):614-7. PubMed ID: 2408194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.
    Rosenqvist E; Holst J; Nøkleby H
    Vaccine; 2007 Jan; 25(6):965-6. PubMed ID: 17052822
    [No Abstract]   [Full Text] [Related]  

  • 7. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New Norwegian vaccine against meningeal infection].
    Bjunne G; Brandtzaeg P
    Sykepleien; 1988 May; 76(10):22-5. PubMed ID: 3388187
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.
    Nøkleby H; Feiring B
    NIPH Ann; 1991 Dec; 14(2):95-101; discussion 101-2. PubMed ID: 1812440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
    Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
    Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccination Project-88. New Norwegian vaccine against type B meningitis--what happened?].
    Rød KA
    Fag Tidsskr Sykepleien; 1990 Jan; 78(1):27-31. PubMed ID: 2109367
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immune response to meningococci].
    Flaegstad T
    Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.
    Høiby EA; Bjune G; Frøholm LO; Eng J; Halstensen A; Rosenqvist E; Rønnild E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):107-21; discussion 121-3. PubMed ID: 1812424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.
    Mueller JE; Borrow R; Gessner BD
    Expert Rev Vaccines; 2006 Jun; 5(3):319-36. PubMed ID: 16827617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
    Marc LaForce F; Ravenscroft N; Djingarey M; Viviani S
    Vaccine; 2009 Jun; 27 Suppl 2():B13-9. PubMed ID: 19477559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.